MET097 Injection

DRUG3 trials

Sponsors

Metsera Inc., Pfizer

Conditions

ObesityObesity in DiabetesType 2 Diabetes Mellitus (T2DM)

Phase 2

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

CompletedNCT06897202

PfizerObesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)

Start: 2025-03-14End: 2026-03-18Updated: 2026-06-12

Phase 3

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)

Not yet recruitingCTIS2025-523974-18-00

Metsera Inc.Obesity

Target: 135Updated: 2026-04-03

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Not yet recruitingCTIS2025-523975-48-00

Metsera Inc.Obesity

Target: 335Updated: 2026-04-16